Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 June 2006, Vol. 107, No. 12, pp. 4871-4879.
Prepublished online as a Blood First Edition Paper on February 28, 2006; DOI 10.1182/blood-2005-08-3272.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-08-3272v1
107/12/4871    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monzo, M.
Right arrow Articles by Sierra, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monzo, M.
Right arrow Articles by Sierra, J.
Related Collections
Right arrow Neoplasia
Right arrow Genomics
Right arrow Clinical Trials and Observations
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia

Mariano Monzo, Salut Brunet, Alvaro Urbano-Ispizua, Alfons Navarro, Granada Perea, Jordi Esteve, Rosa Artells, Miquel Granell, Juan Berlanga, Josep M. Ribera, Javier Bueno, Andreu Llorente, Ramon Guardia, Mar Tormo, Pio Torres, Josep F. Nomdedéu, Emili Montserrat, Jordi Sierra, for CETLAM

From the Hospital Clínic, Hospital Universitario de la Santa Creu i Sant Pau, Hospital de la Vall d'Hebrón, Barcelona; Hospital Germans Trias i Pujol, Badalona; Institut Català d'Oncología, Hospitalet de Llobregat, Hospitalet; Hospital Joan XXIII, Tarragona; Hospital Clínico, Valencia; Hospital Juan Canalejo, ACoruña; Hospital Dr Josep Trueta, Girona; and Department of Human Anatomy, Faculty of Medicine, University of Barcelona, Barcelona, Spain.

Current prognostic factors for acute myeloblastic leukemia (AML) are not sufficient to accurately predict the group of patients in the intermediate-risk category who will successfully respond to treatment. Distinct patterns of inherited functional genomic polymorphisms might explain part of these heterogeneous prognoses. We used the allelic discrimination method to identify polymorphisms in GSTT1, SULT1C2, CDA, SXR (drug metabolic pathways), XPD, XPA, XPG, ERCC1, TOP2A (DNA repair), VEGF (angiogenesis), and MDR1 (multidrug resistance) genes in 110 adult patients with intermediate-risk AML, enrolled in the CETLAM-99 prospective trial. A multivariate prognostic model adjusted for age, white blood cell (WBC) count, French-American-British group, cytogenetics, MLL rearrangement, internal tandem duplication of FLT3 (FLT3-ITD), induction courses to achieve complete remission, and germline polymorphisms, was used to detect independent risk factors associated with clinical outcome. This analysis showed an increased risk of refractoriness to chemotherapy in the group of patients with XPA variant alleles (RR = 14; P = .02). In the same model, increased relapse risk was associated with SULT1C2 heterozygosity (RR = 4.1; P = .004), FLT3-ITD (RR 3.3; P = .003), and MDR1 variant alleles (RR = 2.4; P = .02). Adverse prognostic variables for overall survival were XPA (RR = 3.4; P = .02) and MDR1 (RR = 2.1; P = .02) variant alleles, and WBC count (RR = 2.1; P = .02). These findings might be useful in selecting risk-adapted treatment strategies in intermediate-risk AML.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
M. Granell, A. Urbano-Ispizua, A. Pons, J. I. Arostegui, B. Gel, A. Navarro, S. Jansa, R. Artells, A. Gaya, C. Talarn, et al.
Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation
Blood, November 15, 2008; 112(10): 4337 - 4342.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Hopkins, D. W. Cescon, D. Tse, P. Bradbury, W. Xu, C. Ma, P. Wheatley-Price, J. Waldron, D. Goldstein, F. Meyer, et al.
Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 490 - 499.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020